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INTRODUCTION
Eosinophilic cellulitis (EC), or Wells’ syndrome, was first
described by Wells in 1971 (1). EC is an idiopathic rare dis-
order representing well-circumscribed erythematous pla-
ques with variable appearances, for instances, papulovesicu-
lar, blistering and nodular lesions. There are two stages which
comprise acute cellulitic and chronic granulomatous. Limbs
are the most prevailing sites and trunk is the next. This dis-
order tends to be episodic and lasts from weeks to months
even to years, and heals without scarring (2-4). Histopatho-
logic picture is characterized by a dense diffuse dermal and
sometimes subcutaneous infiltrate predominantly composed
of eosinophils. Degranulated eosinophilic materials and nu-
clear fragments are focally deposited around collagen bun-
dles, forming flame figures, which are distinctive but not
solely confined to EC (5, 6). In addition, blood eosinophilia
is usually present, albeit variable (2, 4). The patients with
EC show variable responses to treatment regimens (2-4).
Cyclosporine has been used in the management of some
immune-mediated cutaneous diseases including hypere-
osinophilic dermatoses (7-14). Thus, we were encouraged to
use cyclosporine in attempts to treat recalcitrant EC. Clear-
ance of the lesions resulted from administration of low-dose
cyclosporine within 1 month. To our search, this is the first
report of patients with EC successfully treated with cyclo-
sporine. We reviewed the pathogenic role of eosinophils and
the usefulness of cyclosporine in EC.
CASE REPORTS
Case 1
A 42-yr-old Korean man presented with reddish swollen
plaques, measuring 11×17 cm, on the right lower abdomen
(Fig. 1). The lesions were slowly increasing in size, and be-
came more edematous and indurated with localized heat
sensation. The eruptions had appeared at the same site sev-
eral times and had persisted for about 1 to 2 months each
time. The patient had no specific medical and family history.
He denied taking any drug before the lesions had developed.
He had neither previous infection symptoms nor insect bites.
He had no previous skin disorders other than chronic urticaria.
On examination, there was no palpable lymph node at axil-
lary or inguinal areas. Laboratory investigations including
ESR, serum glucose, lipid, liver enzymes, BUN, creatinine,
uric acid, and electrolytes were within normal limits. White
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Eosinophilic Cellulitis (Wells' Syndrome) Successfully Treated With
Low-dose Cyclosporine
Eosinophilic cellulitis (Wells’ syndrome) is an uncommon skin disorder. We
report two adult male patients who had recurrent erythematous plaques and a
nodular lesion on the abdomen. The histopathologic feature of their skin biop-
sies similarly indicated a marked infiltrate of eosinophils in the dermis with the
fashion of  “flame figures” . One of the patients demonstrated blood eosinophilia.
Given the clinicohistological findings, the patients fulfilled the criteria for the diag-
nosis of eosinophilic cellulitis. The skin lesions remained refractory to medica-
tions such as corticosteroids, sulfones, antihistamines, and minocycline. Consid-
ering the beneficial effect of cyclosporine in the treatment of eosinophilia-associ-
ated dermatoses, we speculated that eosinophilic cellulitis might respond to
cyclosporine therapy. Thus, each of the two patients was given cyclosporine
(microemulsion formulation) at a daily dose of 1.25 or 2.5 mg/kg, i.e., 100 or 200
mg, respectively. Complete remission of the skin eruptions was obtained in both
patients during a 3- or 4-week period of treatment. No side effects were
observed. Neither of the patients experienced relapse of the disease at least
over 10 months after the discontinuation of the cyclosporine therapy. We sug-
gest that administration of low-dose cyclosporine be a safe and useful therapeu-
tic option in patients with eosinophilic cellulitis. 
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normal range [4.4-10.0×109/L]) with an eosinophilia (28.6%
[0.3-8.0%], eosinophil count 1440/ L [50-500/ L]). Skin
biopsy revealed a diffuse inflammatory infiltrate consisting
mainly of eosinophils with edema in the whole dermis (Fig.
2). Localized necrotic collagen bundles with eosinophilic
granules in the reticular dermis formed flame figures. The
patient was commenced on dapsone (100 mg/day) alone for
2 weeks and in combination with cetirizine (10 mg/day) for
another 2 weeks, together with potent topical corticosteroid,
but with little resolution. 
He revisited 4 months later, complaining of the same skin
problem. Then, microemulsion cyclosporine was adminis-
tered at a daily dose of 1.25 mg/kg, i.e., 100 mg, for 2 weeks,
by which the skin lesions were significantly improved. With
a continuation of the treatment for further 1 week, the lesions
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Fig. 1. Reddish swollen plaques, 11×17 cm, on the right abdo-
men (Case 1).
Fig. 2. Diffuse eosinophilic infiltrate with edema in the dermis
(H&E, ×250, Case 1).
Fig. 3. A gray-blue nodular lesion, 2×5 cm, on the lower abdo-
men (Case 2).
Fig. 4. Dense dermal eosinophilic infiltrate (H&E, ×400, Case 2).were completely cleared. No relapse has been observed over
12 months after the cessation of the therapy.
Case 2
A 25-yr-old Korean man was referred with an asymp-
tomatic skin lesion of 1.5 yr duration. A single and faintly
gray-blue nodule, sized 2×5 cm, was observed on the
lower abdomen (Fig. 3). According to the history, a red-
dened swelling had developed which turned gray-blue nod-
ule and then gradually subsided with a residue of postin-
flammatory hyperpigmentation in 6-8 weeks. The recurrence
intervals were 4-6 months on average. Under no established
diagnosis, he once underwent an intralesional injection of
diluted triamcinolone suspension at a private dermatologic
clinic 1 yr ago, with temporary effect. At the time of pre-
sentation, he has been suffering from iron deficiency anemia
(hemoglobin 7.8 g/dL [12.0-16.0 g/dL]; iron 41  g/dL [50-
130  g/ L]; total iron binding capacity 503  g/dL [280-
400  g/dL]) and has been taking FeSO4. Otherwise, no other
clinical abnormalities were found, nor any drug was pre-
scribed. White cell count, blood chemistry including glu-
cose, lipid, liver enzymes, BUN, creatinine, and electrolytes
were within normal limits except hypertriglycemia (425
mg/dL [10-200 mg/dL]) and increased ESR (46 mm [1-25
mm]). Chest radiography was normal. Skin biopsy showed
a dense dermal eosinophilic infiltrate (Fig. 4). Systemic pre-
dinisolone therapy (40 mg/day) was started which resulted
in no regression of the lesion for 2 weeks. Then, steroid was
discontinued. He was given minocycline (200 mg/day) for
another 2 weeks, with slight improvement. 
He revisited about 3 months later, because of the recurred
nodular lesion. Given the remarkable effect in Case 1, micro-
emulsion cyclosporine was immediately administered at the
same dose (100 mg/day) for 2 weeks and the lesion partially
subsided. The treatment was continued at a daily dose of
2.5 mg/kg, i.e., 200 mg, for further 2 weeks, with complete
remission. No evidence for relapse was noted over 10 months
after the cessation of cyclosporine.
DISCUSSION
Although the mechanism by which EC develops is still
unclear, many factors including viral, bacterial, fungal and
parasitic infections/infestations, arthropod and insect bites,
myeloproliferative disorders and lymphoma, atopy and urti-
caria, and drugs are known to be related to EC (2, 4, 5, 15,
16). However, we doubted urticaria or iron supplement for
anemia in our cases was connected with the development of
EC, in that there was no chronological coherence between
these candidate causal factors and the flare-ups of the lesions. 
Pathogenesis of EC appears to be linked to the immuno-
biology of eosinophils (17). Eosinophils are restricted to and
activated by cytokine activity from helper T (TH2) cells,
which produce interleukin-4 (IL-4) and IL-5. Eosinophils
themselves elaborate such cytokines as interleukins, tumor-
necrosis factor, platelet activating factor, transforming growth
factor, and granulocyte-macrophage colony stimulating fac-
tor. IL-5 attracts eosinophils and up-regulates their adhesion
molecules. Eosinophils produce cytotoxins such as major
basic protein, which contribute to cell membrane damage
and eventually cell death (18). A close correlation between
clinical activity of EC, eosinophils in blood and bone mar-
row, and eosinophil cation protein and IL-5 levels in periph-
eral blood and tissues was described (19). Circulating CD4+
CD7- T cells reportedly play a pivotal role in EC by produc-
ing IL-5 (20). Subset analysis of peripheral T cells revealed
an increased proportion of CD3+CD4+ cells, suggesting
that activated T cells might be implicated in the pathogen-
esis of blood and tissue eosinophilia in EC (21). 
In some patients with EC, oral prednisolone has been of
value and topical corticosteroids have been helpful (2, 4, 15,
16). In other patients, dapsone has been given and has pro-
vided favorable outcomes (2, 3). Remission was reported in
patients treated with a combination of prednisolone, dap-
sone, and antihistamine (22). There have been data justify-
ing the treatment of patients with minocycline (23), while
photochemotherapy (PUVA) has been evaluated to be effi-
cient (24). Not only because these therapeutic options do
not necessarily guarantee credible responses but because
relapse is apt to follow during the treatment intermission, it
is comprehensible that new therapy is required. Typically,
our patients had the lesions that proved resistant to the usual
treatments.
It is apparent that cyclosporine acts primarily on helper T
(CD4+) cells by decreasing their activation, proliferation,
and cytokine production (25). Additionally, an effect of cy-
closporine on eosinophils and basophils in cutaneous inflam-
mation has given rise to the prospect (26). Cyclosporine has
been reported to suppress, in particular, the blood eosino-
phil counts and the production of IL-5 (27), which fuels
speculation that IL-5 may be a therapeutic target in disor-
ders accompanied by eosinophilic inflammation (28). 
Cutaneous diseases associated with increased eosinophils
include drug-induced eosinophilia (7), hypereosinophilic
syndrome (8, 9), eosinophila myalgia syndrome (10), eosi-
nophilic pustular folliculitis (11), eosinophilic fasciitis (12,
13), and angiolymphoid hyperplasia with eosinophilia
(Kimura’ s disease) (14), all of which have already proven
dermatologic conditions amenable to cyclosporine. Besides,
on the grounds that overlap has been documented (15, 29,
30), it is conceivably presumed that a series of eosinophilic
dermatoses may constitute subsets of the wide spectrum of
a non-specific eosinophilic hypersensitivity reaction to a
variety of provoking stimuli. In this sense, it seemed strange
that cyclosporine could never be notified of as one of the
treatment options for EC, which rather hightened our inter-
666 H. Herr and J.K. Kohest in using this agent. The assumption that cyclosporine
might offer improvement was validated by our trial, render-
ing its use promising. Nevertheless, further clinical trials
are man-datory, since the experience of two cases is not
enough to affirm the effectiveness.
Cyclosporine has been used either alone or in combina-
tion with other drugs such as corticosteroids. The dose of
cyclosporine used in the dermatologic field ranges from 1.25
to 5 mg/kg/day, with a dose of 2.5 mg/kg/day or less tenta-
tively defined as “low-dose” (7-14, 28, 31). Strategies to
minimize risk and optimize efficacy have been tailored to
usage guidelines in numerous studies. High cost and toxici-
ty/oncogenicity of cyclosporine have limited its prolonged
use in chronic cutaneous diseases. With our findings, short-
term and low-dose cyclosporine is likely to confer certain
advantage offsetting such drawbacks. 
Contraindications of cyclosporine include past or current
malignancy, uncontrolled hypertension, immunodeficiency,
renal insufficiency, and concurrent infection. Hypertension
and nephrotoxicity have been addressed as the principal ad-
verse effects (31). A daily dose of >5 mg/kg, persistent ele-
vation of creatinine to >30% of baseline and older age are
barometers of the risk factors for cyclosporine-induced ne-
phropathy (32). Oncogenic potential of cyclosporine may
raise concerns about an increasing risk of skin cancers and
lymphoma (31, 33). It is noteworthy that our patients did
not develop hypertension or renal dysfunction during and
after the cyclosporine therapy. 
We conclusively propose that cyclosporine be granted as a
new treatment regimen for refractory EC. Whether to use
cyclosporine as the first-line drug in EC remains to be deter-
mined.
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